How can I participate in a patient registry for eculizumab?

Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Eculizumab ... Not to be confused with ocrelizumab. Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody ... Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Nov 4, 2021 ... FDA approved eculizumab (SolirisTM), the only biologic treatment currently available for gMG for “adult patients who are anti-acetylcholine ... NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ... About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ... Oct 24, 2017 ... The US Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti- ...